Latest Conference Articles

Data show no evidence of increased risk of adverse events in patients aged ≥80 years, compared to patients aged 70 - 79 years.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data presented at ADA 2021 show GLP-1RA treatment is budget neutral in comparison to SoC, citing lower inpatient and outpatient cost.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Data presented at ADA 2021 supports the noninferiority of faricimab to aflibercept.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.

Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.

Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.

Patients with opioid-induced constipation had more frequent, painful constipation symptoms, compared to those with chronic idiopathic constipation.

Direct optical endoscopy are often underutilized in screenings for EAC.

Data show patients with IBD and pathogen produced a unique pathogen-specific microbiome.

Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.

Sucrase isomaltase deficiency is often overlooked symptom in adult patients with IBS-D.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.

Data show adverse events occurred in 6.67% in the cohort of patients with IBD.

Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.

About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.

Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.

The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.

Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.